Market Overview:
The global HER2 inhibitors market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of oncology. The global HER2 inhibitors market is segmented on the basis of type, application, and region. On the basis of type, it is divided into monotherapy and combination therapy. Monotherapy accounted for a larger share of the global HER2 inhibitors market in 2017 owing to its lower cost and higher efficacy as compared to combination therapy. However, combination therapy is expected to grow at a higher CAGR during the forecast period due its ability to provide better outcomes than monotherapy by targeting multiple pathways involved in tumorigenesis simultaneously. On the basis of application, breast cancer accounted for a major share of the global HER2 inhibitors market in 2017 owingtoits high prevalence across all regions studied herein. However,.
 Inhibitors Industry Outlook.svg)
Product Definition:
A HER2 (Human Epidermal Growth Factor Receptor 2) inhibitor is a type of medication used to treat cancer. It works by blocking the action of HER2, a protein that helps tumors grow and spread. Blocking the action of HER2 can help slow or stop the cancer's growth.
Monotherapy:
Monotherapy is the treatment of choice for early-stage HER2 positive breast cancer. It is a type of chemotherapy that delivers only one drug at a time, which targets and eliminates cancer cells with high efficiency. Monotherapy includes small molecule drugs or biologics such as Herceptin (trastuzumab), Avastin (bevacizumab), and Alimta (pomalidomide).
Combination Therapy:
Combo therapy is a combination of two or more drugs used for the treatment of cancer. Some of the most common types are chemotherapy and radiation with/without surgery, hormone therapy (estrogen & progesterone replacement), and vaccine therapy. The goal of this type is to use multiple approaches to combat a disease or condition by using different medications for each aspect that may be helpful in treating various cancers.
Application Insights:
The breast cancer segment dominated the global market in 2017. This is owing to the high prevalence of breast cancer, which has resulted in an increased demand for targeted therapeutics. According to Breastcancer.org, around 1 in 8 U.S women develop invasive breast cancer as per a study published by NCBI in 2014; globally, around 2 million new cases were reported annually till 2012 and 3 million new cases were reported every year from 2013 till 2015.
Furthermore, increasing research & development investments by companies such as Pfizer and Novartis are expected to drive growth over the forecast period due to technological advancements that have led to improved efficacy of existing drugs coupled with introduction of novel molecules for various applications such as solid tumors and hematological malignancies including lung, liver & biliary system cancers and gastrointestinal cancers among others.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the high adoption of HER2 targeted drugs, presence of a large number of players and high healthcare expenditure in this region. Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about early diagnosis, availability of effective treatment options, and increasing disposable income levels. Moreover, government initiatives for improving healthcare infrastructure are likely to contribute toward regional growth during the forecast period. In addition, growing investment by major pharmaceutical companies for developing novel therapeutics will drive revenue generation in this region during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of HER2-positive cancers: The incidence of HER2-positive cancers is increasing at a rapid pace. This is primarily because of the increasing awareness about these cancers and the availability of better diagnostic tests.
- Growing demand for targeted therapies: There is a growing demand for targeted therapies, especially in developed countries. This is because targeted therapies are more effective and cause fewer side effects than traditional chemotherapy regimens.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D to develop new drugs that can target different types of cancer, including HER2-positive cancers. This is likely to lead to the development of more effective and safer HER2 inhibitors in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Research Report
By Type
Monotherapy, Combination Therapy
By Application
Breast Cancer, Gastric Cancer, Ovarian Cancer, Others
By Companies
F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc, Puma Biotechnology, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Report Segments:
The global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors market is segmented on the basis of:
Types
Monotherapy, Combination Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Gastric Cancer, Ovarian Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc
- Puma Biotechnology, Inc
 Inhibitors Market Overview.svg)
Highlights of The HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monotherapy
- Combination Therapy
- By Application:
- Breast Cancer
- Gastric Cancer
- Ovarian Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HER2 inhibitors are medications that block the activity of HER2. This can help to treat various cancers, including breast cancer.
Some of the key players operating in the her2 (human epidermal growth factor receptor 2) inhibitors market are F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc, Puma Biotechnology, Inc.
The her2 (human epidermal growth factor receptor 2) inhibitors market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size & Forecast, 2018-2028
4.5.1 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size and Y-o-Y Growth
4.5.2 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Absolute $ Opportunity
Chapter 5 Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
5.2.1 Monotherapy
5.2.2 Combination Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
6.2.1 Breast Cancer
6.2.2 Gastric Cancer
6.2.3 Ovarian Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
9.6.1 Monotherapy
9.6.2 Combination Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
9.10.1 Breast Cancer
9.10.2 Gastric Cancer
9.10.3 Ovarian Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
10.6.1 Monotherapy
10.6.2 Combination Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
10.10.1 Breast Cancer
10.10.2 Gastric Cancer
10.10.3 Ovarian Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
11.6.1 Monotherapy
11.6.2 Combination Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
11.10.1 Breast Cancer
11.10.2 Gastric Cancer
11.10.3 Ovarian Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
12.6.1 Monotherapy
12.6.2 Combination Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
12.10.1 Breast Cancer
12.10.2 Gastric Cancer
12.10.3 Ovarian Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Type
13.6.1 Monotherapy
13.6.2 Combination Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Size Forecast by Applications
13.10.1 Breast Cancer
13.10.2 Gastric Cancer
13.10.3 Ovarian Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: Competitive Dashboard
14.2 Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche Ltd
14.3.2 Merck & Co., Inc
14.3.3 Novartis AG
14.3.4 Pfizer Inc
14.3.5 Puma Biotechnology, Inc
